OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Update

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 264,011 shares, an increase of 16.4% from the February 12th total of 226,774 shares. Based on an average trading volume of 297,676 shares, the short-interest ratio is presently 0.9 days. Approximately 2.6% of the shares of the company are sold short. Approximately 2.6% of the shares of the company are sold short. Based on an average trading volume of 297,676 shares, the short-interest ratio is presently 0.9 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OSR in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR as of its most recent filing with the Securities & Exchange Commission. 55.30% of the stock is owned by institutional investors.

OSR Trading Up 4.4%

Shares of OSRH opened at $0.47 on Tuesday. The company’s 50 day simple moving average is $0.56 and its 200-day simple moving average is $0.60. The firm has a market cap of $12.06 million, a PE ratio of -0.42 and a beta of 1.54. OSR has a 12-month low of $0.38 and a 12-month high of $4.33.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.